X4 PHARMACEUTICALS INC (XFOR) Fundamental Analysis & Valuation

NASDAQ:XFOR • US98420X2027

Current stock price

4.31 USD
+0.22 (+5.38%)
At close:
4.39 USD
+0.08 (+1.86%)
After Hours:

This XFOR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. XFOR Profitability Analysis

1.1 Basic Checks

  • In the past year XFOR has reported negative net income.
  • XFOR had a negative operating cash flow in the past year.
  • XFOR had negative earnings in each of the past 5 years.
  • XFOR had a negative operating cash flow in each of the past 5 years.
XFOR Yearly Net Income VS EBIT VS OCF VS FCFXFOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M

1.2 Ratios

  • The Return On Assets of XFOR (-27.27%) is better than 69.17% of its industry peers.
  • With a decent Return On Equity value of -42.51%, XFOR is doing good in the industry, outperforming 68.59% of the companies in the same industry.
Industry RankSector Rank
ROA -27.27%
ROE -42.51%
ROIC N/A
ROA(3y)-40.51%
ROA(5y)-54.22%
ROE(3y)-136.53%
ROE(5y)-139.81%
ROIC(3y)N/A
ROIC(5y)N/A
XFOR Yearly ROA, ROE, ROICXFOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K

1.3 Margins

  • XFOR has a Gross Margin of 83.60%. This is amongst the best in the industry. XFOR outperforms 86.71% of its industry peers.
  • The Profit Margin and Operating Margin are not available for XFOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XFOR Yearly Profit, Operating, Gross MarginsXFOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. XFOR Health Analysis

2.1 Basic Checks

  • XFOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • XFOR has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, XFOR has more shares outstanding
  • The debt/assets ratio for XFOR has been reduced compared to a year ago.
XFOR Yearly Shares OutstandingXFOR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
XFOR Yearly Total Debt VS Total AssetsXFOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • XFOR has an Altman-Z score of -0.70. This is a bad value and indicates that XFOR is not financially healthy and even has some risk of bankruptcy.
  • XFOR has a Altman-Z score of -0.70. This is comparable to the rest of the industry: XFOR outperforms 55.88% of its industry peers.
  • A Debt/Equity ratio of 0.41 indicates that XFOR is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.41, XFOR is not doing good in the industry: 69.94% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z -0.7
ROIC/WACCN/A
WACC9.77%
XFOR Yearly LT Debt VS Equity VS FCFXFOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 10.16 indicates that XFOR has no problem at all paying its short term obligations.
  • XFOR's Current ratio of 10.16 is amongst the best of the industry. XFOR outperforms 80.35% of its industry peers.
  • XFOR has a Quick Ratio of 9.98. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.
  • XFOR has a Quick ratio of 9.98. This is in the better half of the industry: XFOR outperforms 79.77% of its industry peers.
Industry RankSector Rank
Current Ratio 10.16
Quick Ratio 9.98
XFOR Yearly Current Assets VS Current LiabilitesXFOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. XFOR Growth Analysis

3.1 Past

  • XFOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.62%, which is quite impressive.
  • Looking at the last year, XFOR shows a very strong growth in Revenue. The Revenue has grown by 1273.21%.
  • The Revenue has been growing by 63.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)79.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.33%
Revenue 1Y (TTM)1273.21%
Revenue growth 3YN/A
Revenue growth 5Y63.56%
Sales Q2Q%79.08%

3.2 Future

  • XFOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.14% yearly.
  • Based on estimates for the next years, XFOR will show a very strong growth in Revenue. The Revenue will grow by 75.96% on average per year.
EPS Next Y74.46%
EPS Next 2Y32.59%
EPS Next 3Y24.11%
EPS Next 5Y19.14%
Revenue Next Year-70.41%
Revenue Next 2Y-26.95%
Revenue Next 3Y44.62%
Revenue Next 5Y75.96%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
XFOR Yearly Revenue VS EstimatesXFOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
XFOR Yearly EPS VS EstimatesXFOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K -2K

More info and screens

Find the best growth stocksShow best growing peers

1

4. XFOR Valuation Analysis

4.1 Price/Earnings Ratio

  • XFOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year XFOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XFOR Price Earnings VS Forward Price EarningsXFOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XFOR Per share dataXFOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as XFOR's earnings are expected to grow with 24.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.59%
EPS Next 3Y24.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XFOR Dividend Analysis

5.1 Amount

  • XFOR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XFOR Fundamentals: All Metrics, Ratios and Statistics

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (3/26/2026, 5:20:03 PM)

After market: 4.39 +0.08 (+1.86%)

4.31

+0.22 (+5.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17
Earnings (Next)04-29
Inst Owners86.47%
Inst Owner Change444.94%
Ins Owners1.07%
Ins Owner Change1.08%
Market Cap376.87M
Revenue(TTM)35.11M
Net Income(TTM)-79.20M
Analysts84.44
Price Target9.52 (120.88%)
Short Float %4.32%
Short Ratio7.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.04%
Min EPS beat(2)26.15%
Max EPS beat(2)37.93%
EPS beat(4)4
Avg EPS beat(4)46.64%
Min EPS beat(4)21.58%
Max EPS beat(4)100.88%
EPS beat(8)4
Avg EPS beat(8)-148.25%
EPS beat(12)7
Avg EPS beat(12)-93.92%
EPS beat(16)9
Avg EPS beat(16)-71.14%
Revenue beat(2)1
Avg Revenue beat(2)14.99%
Min Revenue beat(2)-15.27%
Max Revenue beat(2)45.25%
Revenue beat(4)3
Avg Revenue beat(4)340.87%
Min Revenue beat(4)-15.27%
Max Revenue beat(4)1313.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.67%
PT rev (3m)16.67%
EPS NQ rev (1m)3.47%
EPS NQ rev (3m)7.33%
EPS NY rev (1m)1.95%
EPS NY rev (3m)16.05%
Revenue NQ rev (1m)3.33%
Revenue NQ rev (3m)-12.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.73
P/FCF N/A
P/OCF N/A
P/B 2.02
P/tB 2.36
EV/EBITDA N/A
EPS(TTM)-4.34
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.01
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0.4
BVpS2.13
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.27%
ROE -42.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.6%
FCFM N/A
ROA(3y)-40.51%
ROA(5y)-54.22%
ROE(3y)-136.53%
ROE(5y)-139.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 234.93%
Cap/Sales 8.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.16
Quick Ratio 9.98
Altman-Z -0.7
F-Score4
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)389.87%
Cap/Depr(5y)262.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.33%
EPS Next Y74.46%
EPS Next 2Y32.59%
EPS Next 3Y24.11%
EPS Next 5Y19.14%
Revenue 1Y (TTM)1273.21%
Revenue growth 3YN/A
Revenue growth 5Y63.56%
Sales Q2Q%79.08%
Revenue Next Year-70.41%
Revenue Next 2Y-26.95%
Revenue Next 3Y44.62%
Revenue Next 5Y75.96%
EBIT growth 1Y38.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.59%
OCF growth 3YN/A
OCF growth 5YN/A

X4 PHARMACEUTICALS INC / XFOR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of X4 PHARMACEUTICALS INC (XFOR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to XFOR.


What is the valuation status for XFOR stock?

ChartMill assigns a valuation rating of 1 / 10 to X4 PHARMACEUTICALS INC (XFOR). This can be considered as Overvalued.


What is the profitability of XFOR stock?

X4 PHARMACEUTICALS INC (XFOR) has a profitability rating of 2 / 10.


What is the earnings growth outlook for X4 PHARMACEUTICALS INC?

The Earnings per Share (EPS) of X4 PHARMACEUTICALS INC (XFOR) is expected to grow by 74.46% in the next year.